ALT CHANGES AND ADVERSE EVENTS OF TELBIVUDINE IN HEPATITIS-B PATIENTS-AN EXPERIENCE OF 11 PATIENTS

Zeeshan Ali, Neeta Maheshwary, Uffaq Zara, Siddiqi Ahson, Muhammad Athar Khan

Abstract


Hepatitis-B virus (HBV) infection is a major global health problem. Of the two billion people who have been infected, more than 350 million have chronic hepatitis. It is estimated that 235,000–328,000 people die annually due to liver cirrhosis and hepatocellular carcinoma, we assessed the short term outcomes of treatment with telbivudine in 11 adults aged 14–41 years with HBeAg-positive or HBeAg-negative chronic hepatitis-B (CHB). Treatment of chronic hepatitis-B patients with telbivudine shows 43.1% reduction in serum ALT with no significant adverse effects.

Keywords: Telbivudine, Hepatitis-B Virus, Hepatocellular Carcinoma, HBeAg

Full Text:

PDF

References


Harkisoen S, Arends JE, Van Erpecum KJ, Van den Hoek A, Hoepelman AI. Hepatitis-B viral load and risk of HBV-related liver disease: From East to West? Ann Hepatol 2012;11:164–71.

Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis-B withthe hepatitis-B vaccine. N Engl J Med 2004;351:2832–8.

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis-B virus and hepatitis C virus infections to cirrhosis andprimary liver cancer worldwide. J Hepatol 2006;45:529–38.

Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis-B virus DNA level. JAMA 2006;295:65–73.

Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis-B Virus Study Group. Risk and predictors of mortality associated with chronic hepatitis-B infection. Clin Gastroenterol Hepatol 2007;5:921–31.

Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based onthe level of circulating hepatitis-B viral load. Gastroenterology 2006;130:678–86.

Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor ofmortality and morbidity from HCC and chronic liver disease in aprospective study. Am J Gastroenterol 2006;101:1797–1803.

Safadi R, Xie Q, Chen Y-K. A randomized trial of switching to telbivudine (Ldt) vs. continued lamivudine in adults with chronic hepatitis-B: results of the primary analysis at week 24. J Hepatol 2007;46(S1):S516.

Zhao S, Tang L, Fan X, Chen L, Zhou R, Dai X. Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis-B: a systematic review. Virol J 2010;7:211.

Jiang H, Wang J, Zhao W. Lamivudine versus telbivudine in the treatment of chronic hepatitis-B: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2013;32(1):11–8.

Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis-B. N Engl J Med 2007;357:2576–88.


Refbacks

  • There are currently no refbacks.


Contact Number: +92-992-382571

email: [jamc] [@] [ayubmed.edu.pk]